TACE with or without a drug that blocks ABCB1 for liver cancer
Part of Cancer clinical trials.
This trial tests whether adding an ABCB1 inhibitor to a standard liver cancer treatment called TACE (blocking blood supply and delivering chemo directly into the tumor) works better than TACE alone. You may join if you have a liver tumor that hasn't been treated before and your liver is working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer confirmed by biopsy or special imaging (CT or MRI).
- At least one tumor has not been treated before and is between 3 and 8 cm in size.
- Your liver is working well—no jaundice (yellow skin/eyes), no fluid buildup in the belly (ascites), and no confusion or sleepiness from liver problems.
- You are 18 years or older and can give informed consent.
- If you could become pregnant, you agree to avoid pregnancy for at least 3 months after treatment.
- You have not had prior systemic therapy for advanced liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial tests whether combining TACE (a procedure that blocks blood supply to the tumor) with three medicines (SHR-8068, adebrelimab, and bevacizumab) works better than TACE alone for people with incurable liver cancer that can't be removed surgically.
This trial studies two treatment schedules for unresectable, stage C liver cancer: one using Deb-TACE alone and one using Deb-TACE followed by HAIC. The goal is to see which plan works better for shrinking tumors and improving outcomes.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
This trial tests whether a combination of two treatments—chemoembolization (DEB-TACE) plus chemotherapy given through the liver artery (RALOX-HAIC)—works better than chemoembolization alone for people with large liver cancer tumors (over 7 cm). The goal is to see if the combination shrinks tumors more effectively.
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.